← Leaderboards
Fernando P Polack
Johns Hopkins University
$2,475,462
Attributed
$2,475,462
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $367K · FY2005–13$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$2,475,462 · 3
By mechanism
R01$1,740,596 · 1
R21$367,875 · 1
R56$366,991 · 1
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Nicole Baumgarth$23,275,831
- King-Wai Yau$28,664,002
- Steven R Kleeberger$929,417
- Kam W Leong$23,208,213
- Delisa Fairweather$8,445,799
Others in their field
Top investigators on “Respiratory Syncytial Virus”
- John P Moore · Weill Medical College Of Cornell Univ$32,320,703
- Tina V Hartert · Vanderbilt University$26,560,454
- Lawrence Michael Kauvar · Trellis Bioscience, Inc.$16,848,377
- Natasha Bassam Halasa · Vanderbilt University Medical Center$14,704,905
- Arnold S Monto · University Of Michigan At Ann Arbor$14,469,945
- John V Williams · Vanderbilt University$13,043,731
Research focus
Respiratory Syncytial VirusLungGlycoproteinsVaccine DevelopmentRespiratory Syncytial Virus VaccinesMouse ModelLifeLaboratoriesPreventResponseVirusVaccinesAntigensVaccine EvaluationChildFutureImmunizationInfantDepositionDisease OutbreaksAffinityAntigen-Antibody ComplexContractsEpitopes
Grant awards (7)
Rational design of a respiratory syncytial virus vaccine to prevent asthma$366,991
R56 · FY2013 · AI · contact PI
Vaccine-enhanced respiratory syncytial virus disease$323,350
R01 · FY2009 · AI · contact PI
Vaccine-enhanced respiratory syncytial virus disease$343,232
R01 · FY2008 · AI · contact PI
Vaccine-enhanced respiratory syncytial virus disease$349,524
R01 · FY2007 · AI · contact PI
Vaccine-enhanced respiratory syncytial virus disease$358,865
R01 · FY2006 · AI · contact PI
Vaccine-enhanced respiratory syncytial virus disease$365,625
R01 · FY2005 · AI
Vaccine-enhanced respiratory syncytial virus disease$367,875
R21 · FY2004 · AI